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It is well documented that PPARα and PPARβ/δ share overlapping functions in regulating myocardial lipid metabolism. However,
previous studies demonstrated that cardiomyocyte-restricted PPARβ/δ deﬁciency in mice leads to severe cardiac pathological
development, whereas global PPARα knockout shows a benign cardiac phenotype. It is unknown whether a PPARα-null
background would alter the pathological development in mice with cardiomyocyte-restricted PPARβ/δ deﬁciency. In the present
study, a mouse model with long-term PPARβ/δ deﬁciency in PPARα-null background showed a comparably reduced cardiac
expression of lipid metabolism to those of single PPAR-deﬁcient mouse models. The PPARα-null background did not rescue or
aggravate the cardiac pathological development linked to cardiomyocyte-restricted PPARβ/δ deﬁciency. Moreover, PPARα-null
did not alter the phenotypic development in adult mice with the short-term deletion of PPARβ/δ in their hearts, which showed
mitochondrial abnormalities, depressed cardiac performance, and cardiac hypertrophy with attenuated expression of key factors
in mitochondrial biogenesis and defense. The present study demonstrates that cardiomyocyte-restricted deletion of PPARβ/δ
in PPARα-null mice causes impaired mitochondrial biogenesis and defense, but no further depression of fatty acid oxidation.
Therefore, PPARβ/δ is essential for maintaining mitochondrial biogenesis and defense in cardiomyocytes independent of PPARα.
1.Introduction
Peroxisome proliferator-activated receptors (PPARα, β/δ,
and γ) form a family of ligand-dependent nuclear receptor
transcription factors. It is well-documented that PPARα and
PPARβ/δ are important in transcriptional regulation of car-
diac lipid metabolism [1, 2].
PPARα is abundantly expressed in tissues with an ele-
vated capacity for fatty acid oxidation (FAO), such as brown
fat, liver, heart, and kidney [3]. The important role of PPARα
in controlling cardiac energy metabolism and function
has been established by studies using both loss- and gain-of-
function approaches in animal models [4, 5]. PPARα regu-
lates fatty acid homeostasis via transcriptional activation of
genes encoding key enzymes in fatty acid metabolism. De-
spitediminishedexpressionofFAOgenesandasubsequently
depressed FAO rate in the heart under basal conditions [6],
PPARα-null mice are viable with no overt pathological de-
velopment, but no longer responsive to fasting or diabetes to
upregulate FAO gene expression [7]. Interestingly, lipotoxic
cardiomyopathy in mice with transgenic PPARγ overe-
xpression in the heart can be corrected in the PPARα-null
background [8]. Transgenic PPARα overexpression in the
heart also leads to lipid overload and cardiomyopathy [9].2 PPAR Research
PPARβ/δ is expressed ubiquitously throughout the body and
at relatively high levels in cardiomyocytes [10, 11]. PPARβ/δ
activates expression of genes that are involved in FAO in-
dependent of PPARα in cardiomyocytes [10, 12, 13]. Our
previous studies indicate that an early, long-term, cardiomy-
ocyte-restricted- (CR-) PPARβ/δ deletion in mice impairs
myocardial FAO and bioenergetics, leading to cardiac dys-
function, progressive myocardial lipid accumulation, cardiac
hypertrophy, and congestive heart failure [12, 14]. Impor-
tantly, we recently discovered that PPARβ/δ is essential for
the adult heart to maintain mitochondrial biogenesis and
antioxidant defense [15, 16, 22].
It becomes clear that both PPARα and PPARβ/δ regulate
an overlapping set of genes involved in myocardial FAO
[2,17],albeitcardiacexpressionofPPARαismoreresponsive
than PPARβ/δ to dietary stress [18]. It remains to be deter-
mined whether the absence of PPARα would predispose the
pathological development induced by PPARβ/δ deﬁciency in
the heart due to their overlapping and speciﬁc functions.
While it is clear that PPARβ/δ is important in cardiac mito-
chondrial function under basal conditions, PPARα has also
beenshowntobeinvolvedintheregulationofmitochondrial
function in the heart under certain conditions (e.g., during
the prediabetic, insulin-resistant stage) [19]. However, it is
unknown whether a PPARα-null background would alter
the pathological development in mice with cardiomyocyte-
restricted PPARβ/δ deﬁciency. The present study tested the
hypothesis that PPARα is required for the detrimental eﬀects
of PPARβ/δ deﬁciency in the heart on myocardial FAO
and mitochondrial biology by studying a mouse model of
cardiomyocyte-restricted PPARβ/δ deﬁciency with the ab-
sence of systemic PPARα.
2. Methods
2.1. Mouse Models of PPARα and PPARβ/δ Knockout.
Long-term cardiomyocyte-restricted PPARδ knockout mice
(CR-PPARβ/δ−/−)[ 12, 15] were obtained by mating the
PPARβ/δﬂox/ﬂox line [20] with the α-MyHC-Cre line [21].
Thetamoxifeninduciblecardiomyocytes-restrictedPPARβ/δ
knockout model (TMPD) has been described [22]. It was
obtained by mating the PPARβ/δﬂox/ﬂox line with the α-
MyHC-driven Mer-Cre-Mer (MCM) overexpression [23].
The above resulted lines were mated with PPARα-null mice
[24] to obtain cardiac double knockout lines (CR-Pd/Pa and
T M P D P A ,r e s p . ) .A l lm i c ew e r ei np u r eC 5 7 / B 6b a c k g r o u n d .
Cardiomyocyte-restricted PPARβ/δ knockout was in-
duced in 10 week-old mice by 5 days of Tamoxifen treatment
(2mg/200μLinsunﬂoweroil,intraperitonealinjection).The
short-term eﬀect of PPARβ/δ deﬁciency was assessed in mice
two weeks after the 5-day injection of tamoxifen. There was
no body weight diﬀerence in mice from all of the experi-
mental groups. All experimental procedures were conducted
in accordance with the Guide for Care and Use of Lab-
oratory Animals of the National Institutes of Health and
were approved by the Institutional Animal Care and Use
Committee of the University of Alabama at Birmingham
(UAB).
2.2. Transcript Analyses. Total RNA samples were extracted
from left ventricles using an RNA extraction kit (Qiagen)
according to the manufacturer’s instructions. Quantitative
real-time RT-PCR analyses were carried out using the Roche
LightCycler 480 system (Roche) to determine transcript
levels of target genes. Real-time PCR results from each gene/
primer pair were normalized to results of β-actin and com-
pared across conditions.
2.3. Protein Analysis. Cytoplasmic or nuclear protein sam-
ples were extracted from left ventricles with NE-PER nuclear
and cytoplasmic protein extraction reagents (Thermo Pierce
78833). Western blots were conducted using commercially
available antibodies. The immunoblotting images were cap-
tured using KODAK Image Station 4000R (Carestream
Health Inc.) by developing the membranes in SuperSignal
West substrates (Thermo Scientiﬁc, 34080 or 34076) and
analyzed with KODAK IM software (Ver 4.5.1). All anti-
bodies were purchased from commercial sources: PPARβ/δ,
FABP, CPT1b, and Catalase (Abcam); Glut1, Glut4, PGC-1α,
Cyt b, DRP1, Fis1, SOD2, and GAPDH (Santa Cruz Biotech-
nology); TFam (Aviva); Cyt C (Invitrogen); Mfn2, and pan-
actin (Sigma Aldrich); SOD1 (Biodesign International).
2.4. Analysis of Mitochondrial DNA Copies. The mitochon-
drial DNA copy number was evaluated by adapting to meth-
ods described previously [25]. Total genomic DNA was iso-
lated from left ventricles, processed by standard procedures
usingaDNAextractingkit(Qiagen),digestedwithNcoI,and
subjected to real-time qPCR analysis. Cytochrome b (cytb)
was employed as a mitochondrial DNA (mtDNA) marker
and the regulator of calcineurin 1 (rcan1) as a nuclear DNA
(nDNA) marker to quantify the amount of mtDNA.
2.5. Analyses of Myocardial TAG. Myocardial triglyceride
contentsinadultmicewereassayedusinglipiddiagnostickits
(Wako Chemicals USA, Inc.). Fresh samples were used and
harvested from mice subjected to fed (35-week old) or 12-
hour fasting conditions (50-week old). For myocardial lipid
extraction, left ventricular tissues were homogenized with
ice-cold chloroform-methanol-water mixture (2:1:0.8) for
2min. Additional chloroform and water were added to sep-
arate the organic and aqueous layers. After centrifugation,
theaqueouslayerwasremoved,andthechloroformlayerwas
d e c a n t e da n de v a p o r a t e da t7 0 ◦C. The residue was dissolved
in 0.5mL of isopropanol.
2.6. Transmission Electron Microscopy (TEM). To obtain
tissue for TEM, hearts of anesthetized mice were perfused
under gravity with 3.5% glutaraldehyde in cardioplegic solu-
tion (25mmol/L KCl, 5% dextrose in PBS, pH 7.4) for two
minutes followed by perfusion with 3.5% glutaraldehyde in
a 0.1mol/L cacodylate buﬀer, pH 7.3 for another 2 minutes.
We take a section (1mm cubed) from the apex of the left
ventricle. Sections were assessed by toluidine blue staining,
and the longitudinal sections were examined by TEM.PPAR Research 3
2.7. [9, 10-3H] Palmitate Oxidation and [14C] Glucose Oxida-
tion Assay in Isolated Working Heart. We measured the rate
of palmitate and glucose oxidation using an isolated working
heart preparation as described previously [16, 26]. The
mouse heart was perfused with Krebs-Henseleit solution
containing 3% BSA (essentially FA, Intergen Corporation),
5mmol/L glucose, 100μU/mL insulin, and 0.4mmol/L pal-
mitate. Hearts were perfused at a constant left atrial preload
pressure of 7mmHg and a constant aortic afterload pressure
of 50 mmHg. Myocardial FA and glucose oxidation rates
were determined by quantitative collection of 3H2Oo r
14CO2 produced by hearts perfused with buﬀer containing
[9,10-3H] palmitate (0.1μCi/mL, MP Biomedicals) and [U-
14C] glucose (0.1μCi/mL, MP Biomedicals) for palmitate
oxidation and glucose oxidation, respectively. 3H2O that was
produced during palmitate oxidation was separated with
a water vapor exchange method [27]. Palmitate oxidation
r a t e sw e r ec a l c u l a t e df r o m3H2O production, taking into ac-
count the vapor exchange eﬃciency. 14CO2 produced during
glucose oxidation was collected using a CO2 trapping meth-
od [28].
2.8. Mitochondrial Oxidative Stress. Oxidative stress of car-
diac mitochondria was accessed using freshly isolated mito-
chondria, which were prepared with mitochondria isolation
kits (SIGMA, MITOISO1) according to the protocols pro-
vided. Mitochondria potential was determined using the JC-
1 assay kit (SIGMA) according to the manufacturer’s in-
struction. Fiveμg of mitochondria protein in 75μL of the
JC-1 assay buﬀer was used. The relative ﬂuorescence of the
sample was measured using a time-drive method in a spec-
troﬂuorescent multiwell plate reader (Synergy HT, Bio-
Tek) with485/20nm (excitation), 590/35nm (emission). Ac-
onitase activity was measured spectrophotometrically based
on the instruction of the manufacturer (Sigma) with modi-
ﬁcation for a 96- well plate assay. The activity was calculated
using Vmax.
2.9.EchocardiographyMeasurement. Asdescribedpreviously
[16, 26], a high-resolution echocardiograph system (Visual-
sonics VEVO 770 System) was used to assess cardiac struc-
ture/function in vivo with a 35MHz probe at various time
points and before terminal experiments. Mice were anaes-
thetized by isoﬂurane inhalation. Heart rate was maintained
at ∼450 beats per minute, and the body temperature was
maintained at 37◦C by placing mice on a heating pad. We
obtained IVS (intraventricular septum thickness), LVID (left
ventricularinternaldimension),LVvolume,LVPW(leftven-
tricularposteriorwallthickness),EF%,andFS%underlong-
axis M-mode. All data and images were saved and analyzed
by an Advanced Cardiovascular Package Software (Visual-
sonics VEVO 770 System).
2.10. Statistics Analysis. Data for comparison of two groups
were analyzed using Student’s t-test; otherwise, the data were
analyzed by one factor or mixed, two-factor analysis of Vari-
ance (ANOVA) using GraphPad Prism software (GraphPad
Software Inc.). Values of quantitative results were expressed
as mean ± SEM. Diﬀerences between groups and treatments
were regarded as signiﬁcant at the P<0.05 probability level.
3. Results
3.1. Early and Long-Term Cardiac PPARβ/δ Deﬁciency in
PPARα-Null Mice Leads to Phenotypic Changes Consistent
with CR-PPARβ/δ−/− Mice. We crossed the cardiomyocyte-
restricted PPARβ/δ line (CR-PPARβ/δ−/−) with the PPARα-
null line (PPARα−/−) to generate a mouse line with early and
long-term cardiac PPARβ/δ deﬁciency in PPARα-null back-
ground (CR-Pd/Pa-null) mice. Real-time PCR conﬁrmed
that PPARα and PPARβ/δ in the CR-Pd/Pa-null heart were
knockout or knockdown (Figure 1(a)). The CR-Pd/Pa-null
hearts exhibited the attenuation of FAO genes, such as CD36,
heart type fatty acid binding protein (FABP), carnitine pal-
mitoyl transferase-Ib (CPT-Ib), and acyl-Coenzyme A dehy-
drogenase medium chain (ACADM), which was similar to
either PPARα-null or CR-PPARβ/δ−/− hearts (Figure 1(b)).
Myocardial triglyceride contents were comparably elevated
in fasting PPARα-null, CR-PPARβ/δ−/−, and CR-Pd/Pa-null
mice (Figure 1(c)) and elevated only in fed CR-PPARβ/δ−/−
and CR-Pd/Pa-null mice (Figure 1(d)). As with CR-
PPARβ/δ−/− mice, CR-Pd/Pa-null mice exhibited cardiac
hypertrophy, with an increased heart weight/body weight
ratio and ventricular expression of the atrial natriuretic fac-
tor (ANF) after ∼35 weeks of age (Figures 2(a) and 2(b)).
Ultrastructural changes in CR-Pd/Pa-null hearts were iden-
ticaltothoseinCR-PPARβ/δ−/− hearts,whichdisplayedsub-
stantial mitochondrial shrinkage and depletion, increased
numberandsizesoflipiddroplets andsarcomericdisruption
(Figure 2(c)). Mitochondrial volume and mitochondrial
DNA copy number were decreased in the CR-PPARβ/δ−/−
andCR-Pd/Pa-nullmice(Figures1aandbinSupplementary
Material available at doi: 10.1155/2011/372854). Similar to
CR-PPARβ/δ−/−, most of the CR-Pd/Pa-null mice died from
heart failure by 13 months of age (Figure 2(d)). These re-
sults demonstrate the essential roles of PPARβ/δ in cardiac
structure/function for all developmental stages through
adulthood.
3.2. Short-Term Cardiac PPARβ/δ Deﬁciency in PPARα-
Null Mice Does Not Further Suppress Myocardial Lipid
Metabolism. To investigate the eﬀects of short-term cardiac
PPARβ/δ deﬁciency in adult PPARα-null mice, we fur-
ther studied tamoxifen inducible cardiomyocyte-restricted
PPARβ/δ/PPARα double knockout (TMPDPA) mice. As
expected, PPARβ/δ was comparably decreased in the tamox-
ifen inducible cardiomyocyte-restricted PPARβ/δ knockout
(TMPD) and TMPDPA hearts two weeks after tamoxifen in-
jection,whereasitwasunchangedinPPARα-nullandtamox-
ifen inducible MerCreMer (TMCM) hearts (Figure 3(a)).
PPARγ expression was not changed in any of the above
mouse lines (Figure 3(a)). The TMPD and TMPDPA
hearts showed decreased PPARβ/δ protein compared with
PPARα-null and TMCM hearts (Figure 3(b)). Consequently,
transcript levels of representative genes encoding essential4 PPAR Research
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Figure 1: Transcript levels measured by real-time RT-PCR analyses. (a) Transcript expression levels of PPARα and PPARβ/δ in CR-Pd/Pa-
null and α-MyHC-Crehearts.RNAsamples were extracted fromheartsof 35-week-old mice. (b)Transcript expressionlevels of CD36,FABP,
CPT-Ib, ACADM, and MCD in α-MyHC-Cre, CR-PPARβ/δ−/−,P P A R α−/−, and CR-Pd/Pa-null hearts. RNA samples were extracted from
hearts of ∼35-week-old mice. (c) Myocardial triglyceride content was measured in mice subjected to fasting. (d) Myocardial triglyceride
content was measured in mice without fasting.
proteins in lipid metabolism, such as CD36, ACADM, acyl-
Coenzyme A dehydrogenase long chain (ACADL), MCD,
CPT-Ib, uncoupling protein 2 (UCP2), and FABP, were
downregulated in PPARα-null and TMPDPA compared with
the control (TMCM) hearts (Figure 3(c)). Except for CD36
and ACADL, the above genes were also downregulated in
TMPD hearts (Figure 3(c)). CPTII was decreased in
PPARβ/δ-deﬁcient hearts (Figure 3(c)). For protein levels,
PPARα-nullheartsexhibiteddecreasedCPT-IbbutnotFABP
(Figure 3(d)), whereas TMPD and TMPDPA hearts exhib-
ited decreased CPT-Ib and FABP (Figure 3(d)). Transcript
expression of proteins that are important in glucose metab-
olism, such as Glut1 and PFK, was markedly increased in
mice with PPARα deﬁciency (Figure 3(e)). Interestingly,
Western blot revealed that Glut4, but not Glut1, was elevated
in all the knockout (KO) lines (Figure 3(f)).
3.3. Short-Term Cardiac PPARβ/δ Deﬁciency Leads to
Depressed Mitochondrial Biogenesis Independent of PPARα.
OurrecentstudydemonstratedthatPPARβ/δ playsanessen-
tial role in regulating the transcriptional expression of key
determinants of mitochondrial biogenesis [22]. Here we fur-
ther assessed whether short-term additional PPARβ/δ deﬁ-
ciencyinPPARα-nullmicewouldexacerbatethiseﬀect.Real-
time PCR revealed that NRF1, NRF2a and b, and PGC1α
and β were all downregulated in TMPD hearts (Figure 4(a)).
In addition, mitochondrial transcription factor A (TFAM)
was also downregulated in TMPD hearts (Figure 4(a)). In
contrastwithTMPDhearts,PPARα-nullheartsdid not show
changes in any of these important determinants of mito-
chondrial biogenesis (Figure 4(a)). The doubly deﬁcient
hearts displayed a comparable downregulation of the above
genes, except for NRF1, NRF2a, and PGC1b (Figure 4(a)).
Protein expression of key mitochondrial determinants, such
as PGC-1α and TFAM, was decreased by about 30–40% and
50–60%, respectively, in TMPD and TMPDPA, but not in
PPARα-null hearts (Figure 4(b)). The transcript levels of mi-
tochondrial proteins, such as cox2, cox3, cyto c, and cyto
b, were downregulated in TMPD hearts, whereas cox2 and
cyto c were downregulated in TMPDPA hearts (Figure 4(c)).
There was no change in these transcript levels for PPARα-
null hearts (Figure 4(c)). Western blotting revealed that
the protein levels of cyto b were downregulated in TMPDPPAR Research 5
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Figure 2: Cardiac pathology and survival rate. (a) Cardiac hypertrophy was estimated by heart weight/body weight ratio. (b) Transcript
expression levels of ANF in α-MyHC-Cre and CR-Pd/Pa-null hearts. (c) Assessment of cardiac ultrastructure by Transmission Electron
Microscopy (TEM): representative images are shown of heart sections from α-MyHC-Cre, PPARα−/−,C R - P P A R β/δ−/−, and CR-Pd/Pa-null
mice at the age of 35 weeks (image magniﬁcation: 12,000x). Arrows indicate lipid droplet. (d) Kaplan-Meier survival curves: survival rates
of mice from α-MyHC-Cre, CR-PPARβ/δ−/−, CR-Pd/Pa-null, and control groups after 15 months were analyzed by the log-rank test (CR-
PPARβ/δ−/− or CR-Pd/Pa versus α-MyHC-Cre, P<0.001).
and TMPDPA hearts (Figure 4(d)). Interestingly, cardiac
expression of cyto c protein was downregulated in all three
PPAR-deﬁcient lines (Figure 5(d)). The transcript expression
of mitochondrial proteins involved in mitochondrial ﬁssion
and fusion, such as Fis1 and mitofusin 2, was downregulated
in both TMPD and TMPDPA hearts (Figure 4(e)). DRP1
was slightly increased in TMPDPA, but not in PPARα-a n d
PPARβ/δ-deﬁcient hearts (Figure 4(e)). Protein levels of Fis1
were decreased in TMPDPA hearts (Figure 4(f)). Mitofusin
2 protein was decreased in both TMPD and TMPDPA,
but not in PPARα-null hearts (Figure 4(f)). Consequently,
both TMPD and TMPDPA, but not PPARα-null hearts,
exhibited a similar attenuation of the mitochondrial DNA
copy number (Figure 4(g)).
3.4. Short-Term Cardiac PPARβ/δ Deﬁciency Leads to
Depressed Endogenous Anti Oxidants and Increased Oxidative
Stress Independent of PPARα. We next examined whether
PPARα is involved in the transcriptional regulation of
important endogenous anti oxidants in the heart. The
transcript and protein expression of both SOD1 and SOD2
was decreased in TMPD and TMPDPA, but not in PPARα-
null hearts, relative to control hearts (TMCM) (Figure 5(a)).
Protein expression of both SOD1 and SOD2 was decreased6 PPAR Research
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Figure 3: Expression of key proteins in fatty acid and glucose metabolism. (a) Real-time PCR results for transcript expression of PPARα,
PPARβ/δ,a n dP P A R γ on RNA samples extracted from ventricular tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice. (b) Western
blotting results of PPARβ/δ protein levels in nuclear proteins from ventricular tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice.
(c) Transcript level of fatty acid metabolism genes in samples from ventricular tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice.
Expressions of CD36, ACADM, ACADL, MCD, CPT1b, CPTII, UCP2, and FABP are shown. (d) Protein levels of FABP and CPT-Ib in
samples from ventricular tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice. (e) Transcript levels of Glut1, Glut4, HK2, and PFKII
in samples from ventricular tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice. (f) Protein levels of Glut1 and Glut4 in samples from
ventricular tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice.
∗P < 0.05 versus TMCM;
∗∗P < 0.01 versus TMCM.PPAR Research 7
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Figure 4: Expression of key determinants of mitochondrial biogenesis and mitochondrial proteins. (a) Real-time PCR measurement of
transcriptlevelsofNRF-1,NRF2(aandbsubunits),PGC-1αand-1β,andTFAMonsamplesfromTMCM,PPARα−/−,TMPD,andTMPDPA
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tissues of TMCM, PPARα−/−, TMPD, and TMPDPA mice. (c) Transcript expression of mitochondrial proteins on samples from TMCM,
PPARα−/−, TMPD, and TMPDPA hearts. (d) Protein expression of mitochondrial proteins on samples from TMCM, PPARα−/−, TMPD,
and TMPDPA hearts. (e) Transcript expression of mitochondrial ﬁssion and fusion proteins on samples from TMCM, PPARα−/|−, TMPD,
and TMPDPA hearts. (f) Protein expression of mitochondrial ﬁssion and fusion proteins on samples from TMCM, PPARα−/−, TMPD, and
TMPDPA hearts. (g) The mitochondrial DNA copy number on samples from TMCM, PPARα−/−, TMPD, and TMPDPA hearts.
∗P < 0.05
versus TMCM;
∗∗P < 0.01 versus TMCM.
in TMPD and TMPDPA hearts (Figures 5(b) and 5(c)).
Interestingly, catalase protein expression was decreased only
in TMPDPA hearts (Figure 5(d)). TMPD and TMPDPA, but
notPPARα-null,heartsexhibitedaugmentedoxidativestress,
illustrated by depressed aconitase activity and mitochondrial
membrane potential (JC-1) compared with controls (Figures
5(e) and 5(f)).
3.5. Short-Term Cardiac PPARβ/δ Deﬁciency Leads to
Depressed Myocardial Fatty Acid Oxidation, Cardiac Dysfunc-
tion, and Cardiac Hypertrophy Independent of PPARα. We
assessed the rate of myocardial oxidative metabolism and
cardiac function in the isolated working heart for the four
experimental groups. As expected, the palmitate oxidation
rates in PPARα-null, TMPD, and TMPDPA hearts were sim-
ilarly downregulated compared with control mice (TMCM)
(Figure 6(a)). Only PPARα-null hearts showed an increase
in glucose oxidation (Figure 6(b)). The isolated working
heart studies revealed that short-term deﬁciency of PPARβ/δ
led to depression of cardiac contraction with decreased left-
ventricular systolic pressure (LVSP), LV developed pressure
(LVPamp), and dLVPdtmax (Table 1). Noninvasive echocar-
diographic measurement revealed that TMPD and TMPDPA
hearts displayed increased intraleft ventricular dimension
(LVID) with thickening intraventricular septa (IVS), in-
creased LV mass, and decreased ejection fraction (Table 2).
Fractional shortening and the rate of deceleration of mitral
valve ﬂow (MV Decel rate) were decreased (Table 2).
4. Discussion
The coexistence of the three PPAR subtypes in cardiomy-
ocytes is now well established [4, 6, 10–12, 29–31]. It be-
comes clear that the three PPAR subtypes share many of
their functions in the transcriptional regulation of lipid me-
tabolism [10, 11, 26, 29]. This is especially true for PPARα
and PPARβ/δ, which are relatively abundant in cardiomy-
ocytes. However, there are still gaps in our knowledge re-
gardingtheinterrelationshipofthesesubtypes.Inthepresent
study, we test the hypothesis that PPARα is required for the
detrimental eﬀects of PPARβ/δ deﬁciency in the heart on
myocardial FAO and mitochondrial biology. It is a sur-
prise that cardiomyocyte-restricted deletion of PPARβ/δ in
PPARα-null mice causes impaired mitochondrial biogenesis
and defense, but no further depression of FAO.
The most striking pathological changes shared by
PPARβ/δ KO and PPARα/PPARβ/δ double KO hearts are
mitochondrial abnormalities, such as shrinkage and deple-
tion. Mitochondrial DNA copy numbers were also substan-
tially decreased. There were many lipid droplets with
large sizes and disrupted sarcomere found in their ultra-
structure. To minimize potential confounding eﬀects of
development (before adulthood) and severe pathology in
long-term PPARβ/δ-deﬁcient hearts, we further investigated
mice with short-term (∼14 days after tamoxifen induction)
cardiomyocyte-restricted PPARβ/δ (TMPD) in the adult
heart. As expected, the transcriptional expression of key
determinants of mitochondrial biogenesis, along with many
mitochondrial proteins, was decreased in PPARβ/δ-deﬁcient
hearts with or without PPARα compared with PPARα-null
and controlled hearts. The expression of anti oxidants, such
as SOD1 and SOD2, was also the same. As a result, mito-
chondrial DNA copy number and mitochondrial oxidative
stress were impaired only in TMPD and TMPDPA mouse
hearts. Therefore, these deﬁciencies should be attributed to
the phenotypic changes in mice with PPARβ/δ deﬁciency,PPAR Research 9
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Figure 5: Endogenous anti oxidants and oxidative stress. (a) Real-time PCR analysis of transcript expression of SOD1, SOD2, and catalase
on samples from TMCM, PPARα−/−, TMPD, and TMPDPA hearts. (b, c, and d) Western blotting analysis of protein levels of SOD1, SOD2,
and catalase on samples from TMCM, PPARα−/−, TMPD, and TMPDPA hearts. (e) Mitochondrial membrane potential estimated by JC-1
uptakeassayinisolatedmitochondriafromTMCM,PPARα−/−,TMPD,andTMPDPAhearts.(f)Mitochondrialaconitaseactivityofsamples
from TMCM, PPARα−/−, TMPD, and TMPDPA hearts.
∗P < 0.05 versus TMCM;
∗∗P < 0.01 versus TMCM.10 PPAR Research
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Figure 6: Rates of oxidative metabolism and cardiac function. (a) The rate of palmitate oxidation in isolated working hearts from TMCM,
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versus TMCM.
supporting the notion that cardiac PPARβ/δ is an inde-
pendent, essential transcriptional regulator of mitochondrial
biogenesis and the mitochondrial anti-oxidant defense sys-
tem in the heart. Cardiac PPARα may not be required or its
deﬁciency may be compensated by unknown mechanisms.
It has been shown that PPARα determines mitochondrial
biogenic responses in insulin-resistant hearts [8]. Therefore,
it is possible that the eﬀects of PPARα on myocardial mito-
chondrial biogenesis are responsive only to speciﬁc physio-
logical or pathological stresses, which is similar to its re-
sponse to fasting condition [7, 18].
It is surprising that cardiac deﬁciency induced by
PPARα/PPARβ/δ deﬁciencies did not further impair the
expression of most FAO genes. It is plausible that the heart
possesses other mechanisms for maintaining a minimal level
of lipid metabolism. We recently showed that PPARγ in the
adultheartalsoplaysa rolein regulatingfattyacidutilization
[32]. Although PPARγ expression was not changed in any of
the experimental groups in this study, we could not rule out
the possibility that PPARγ helps maintain the minimal level
of oxidative metabolism via increasing its activity. Although
the PPARα-null heart displayed a similarly suppressed
myocardial lipid metabolism, no overt phenotype could be
detected in these mice under basal conditions during adult-
hood. In contrast, phenotypic changes in the long-term
double KO mice were largely identical to those of PPARβ/δ
monogenic KO mice [12] with the progressive development
ofcardiachypertrophy,mitochondrialdepletion,andprema-
turedeath.Therefore,itappearsthatimpairedmitochondrial
biogenesis and exacerbated oxidative damages, in addition to
myocardial FAO deﬁciency, accounts, for the severe pheno-
typic changes in PPARβ/δ-deﬁcient hearts.
Even though cardiac PPARβ/δ KO in TMPD mice ap-
pears to be less complete compared with CR-PPARβ/δ−/−
mice, it is suﬃcient to impair the expression of major lipid
metabolism genes. In fact, the PPARα and PPARβ/δ single
KO and the double KO lines exhibited similarly impaired
rates of myocardial FAO. While myocardial lipid accumu-
lation is consistently increased in PPARβ/δ-deﬁcient mouse
hearts with or without PPARα, this is not as apparent in the
short-term PPARβ/δ-deﬁcient hearts. It is therefore likely,
but remains to be proven, that the adult heart possesses a
greater capacity for handling excessive unburned fat than
doesthenewbornheart.However,thevoidofPPARβ/δ inthe
adult heart is suﬃcient to cause cardiac dysfunction. Ex vivo
and in vivo cardiac function assessment revealed that both
systolic and diastolic dysfunction can be detected in mice
with PPARβ/δ deﬁciency in their hearts, consistent with the
increased left ventricular mass.
Interestingly, expression of Glut1 and PFKII transcripts
was increased in both PPARα-null and the TMPDPA, but
not in PPARβ/δ single deﬁcient hearts. Moreover, Glut4 pro-
tein levels were upregulated in all PPAR deﬁcient hearts,
but only PPARα-null hearts exhibited greater rates of glu-
coseoxidation.TMPDheartsmaintainednormalglucoseox-
idation in this set of study and was decreased in the previous
study [22]. The lack of dysfunction in the PPARα-null com-
pared with PPARβ/δ deﬁciency hearts could be either of
the following (1) normal mitochondria allowing greater
capacity in glucose oxidation and insulin sensitivity: and (2)
diﬀerences in the storage or types of stored lipids. It is likely
that the impaired mitochondrial capacity due to PPARβ/δ
deﬁciency prevents the upregulation of glucose oxidation.
The upregulation of glucose utilization should be attributed
to the well-maintained cardiac function in PPARα-null
hearts. It is conceivable that the compensatory responses
occur at both transcriptional and translational levels. How-
ever, it is obvious that this compensation is not suﬃcient
for the TMPDPA heart to overcome the mitochondrial de-
fects derived from PPARβ/δ deﬁciency. It is intriguing that
PPARβ/δ deﬁciency in cultured adult cardiomyocytes leads
to depression of both FAO and glucose oxidation [22].
However, the current study based on isolated hearts revealed
that FAO, but not glucose oxidation, was depressed in
PPARβ/δ-deﬁcient hearts. It is likely that glucose oxidation
is better conserved in the ex vivo hearts or it is due toPPAR Research 11
Table 1: Hemodynamic measurement of isolated working heart.
Parameters TMCM Pa TMPD TMPDPA
HR 431 ± 20 435 ± 22 410 ± 23 406 ± 16
LVPsys (mmHg) 110.8 ± 3.9 110.5 ± 2.3 94.7 ± 5.6∗ 105.0 ± 1.7
LVEDP (mmHg) 7.8 ± 1.8 7.8 ± 1.6 9.8 ± 2 12.5 ± 2.8
LVPdia (mmHg) 2.4 ± 1.3 3.7 ± 1.2 5.7 ± 1.8 7.3 ± 3.4
LVPamp (mmHg) 108.4 ± 3.8 106.8 ± 2.6 84.0 ± 5.7∗∗ 91.7 ± 5.3∗
dLVPdtmax (mmHg/s) 6691 ± 518 5999.7 ± 361 5154 ± 332∗ 5500.9 ± 683.7
−dLVPdtmin (mmHg/s) −5666 ± 428 −4741 ± 330.6 −4635.8 ± 338 −4836.2 ± 614.9
Heart rate: HR; left ventricular systolic pressure: LVPsys; left ventricular end-diastolic pressure: LVEDP; left ventricular diastolic pressure: LVPdia; left
ventricular developed pressure: LVPamp; left ventricular developed pressure; ﬁrst derivative (dLVPdtmax and dLVPdtmin), ∗P<0.05 versus TMCM, n = 5–8.
Table 2: Echocardiography measurement in mice ∼two weeks after the end of tamoxifen treatment.
Parameters TMCM Pa TMPD TMPDPA
IVS;d (mm) 0.77 ± 0.02 0.81 ± 0.04 0.95 ± 0.06∗ 0.96 ± 0.02∗
IVS;s (mm) 1.29 ± 0.06 1.16 ± 0.08 1.30 ± 0.05 1.12 ± 0.05
LVID;d (mm) 3.65 ± 0.06 3.85 ± 0.11 3.91 ± 0.11 3.65 ± 0.09
LVID;s (mm) 2.2 ± 0.09 2.12 ± 0.09 2.54 ± 0.11∗ 2.62 ± 0.09∗
LVPW;d (mm) 0.69 ± 0.03 0.67 ± 0.05 0.76 ± 0.04 0.61 ± 0.02
LVPW;s (mm) 1.13 ± 0.04 0.99 ± 0.06 1.13 ± 0.06 1.05 ± 0.02
Ejection Fraction (%) 71.5 ± 1.5 73.66 ± 1.68 64.71 ± 2.41∗ 60.57 ± 2.31∗
Fractional Shortening (%) 40.1 ± 2 41.9 ± 1.39 35.01 ± 1.84∗ 31.93 ± 1.59∗
MV Decel rate (mm/s2) −38144 ± 1666 −30433 ± 2693 −23192 ± 828∗ −19992 ± 2873∗
HR (Beat/Min) 414 ± 7 406 ± 13 417 ± 25 390 ± 14
LV mass/BW 3.29 ± 0.13 3.50 ± 0.1 4.05 ± 0.2∗ 4.05 ± 0.12∗
IVS;d and IVS;s: interventricular septum (diastole and systole); LVID;d and LVID;s: left ventricular internal diameter (diastole and systole); LVPW;d and
LVPW;s: left ventricular posterior wall (diastole and systole); EF%: ejection fraction; FS%: fractional shortening. MV decal rate: mitral valve deceleration rate;
HR: heart rate, LV mass/BW: ratio of left ventricular mass to body weight. ∗P<0.05 versus TMCM n = 8.
indirect compensatory upregulation similar to, but not as
robust as, those in PPARα-null hearts. Indirect responses
may also be the causes of certain disagreements in the ex-
pression pattern between the transcript and protein levels.
For example, cardiac expression of FABP was downregulated
at transcript level but not at protein level in PPARα-null
hearts. Slight diﬀerences in time points, sample handling,
tamoxifen absorption, reagents from diﬀerent lots may also
contributetotheinconsistencies.However,theoverallpatho-
physiological changes are highly consistent in the short-term
PPARβ/δ-deﬁcient hearts in this study and the previous
study [22].
Although double knockout of PPARα and PPARβ/δ led
to largely similar depression in expression of key metabolic
and mitochondrial proteins, it is noted that certain degrees
of interaction between the two PPAR subtypes may occur in
the double knockout heart. Compared with the control and
TMPDhearts,Glut1andPFKIItranscriptswereupregulated;
NRF1, NRF2a, and PCG1b transcripts were unchanged in
double deﬁcient hearts. However, these potential changes
due to the voids of both PPAR subtypes appear to be in-
suﬃcient to rescue the impaired mitochondrial structure/
function. Burkart et al. have previously demonstrated in
gain-of-function studies that PPARα and PPARβ/δ have
distinct roles in regulating glucose metabolism. Speciﬁcally,
they documented diﬀerential regulation of Glut4 via a my-
o c y t ee n h a n c e rf a c t o r( M E F )r e s p o n s ee l e m e n t[ 13]. It is
plausible that an upregulation of cardiac Glut4 found in the
three PPAR-deﬁcient lines is due to compensatory responses
regulating by MEF pathway and/or other signaling pathways.
In summary, the present study demonstrates that the
double deﬁciency of PPARα and PPARβ/δ in the heart does
not aggravate the impairment of myocardial FAO. PPARα
deﬁciency does not alter the unique function of PPARβ/δ
as an essential regulator of cardiac mitochondrial protection
and biogenesis in the heart. Therefore, we conclude that
PPARβ/δ is essential for myocardial mitochondrial function
independent of PPARα.
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